Introduction
Haematopoietic SCT (HSCT) is a well-established approach for the treatment of several haematologic, metabolic and neoplastic disorders. 1 However, HSCT is not an innocuous procedure and may be associated with several early and late life-threatening complications. Those complications that appear early after HSCT are usually caused by the toxicity of the conditioning regimen, infections or immune reactions (mainly GVHD). In addition, in this initial phase, there is an interesting group of complications that do not have well-established origins. The most relevant are sinusoidal obstruction syndrome, capillary leak syndrome, engraftment syndrome, transplant-associated microangiopathy (TAM), diffuse alveolar haemorrhage, and idiopathic pneumonia syndrome. All these complications share the following characteristics: they have an early onset after HSCT, overlapping clinical manifestations, the absence of well-defined clinical criteria for diagnosis (and consequently an unknown true incidence), the absence of well-established treatments, and the tendency to evolve to an irreversible multiorgan dysfunction syndrome.
What is known about the pathogenesis of these syndromes?
Sinusoidal obstruction syndrome, commonly called hepatic veno-occlusive disease (VOD), is the most frequent and well studied of these complications and the only one with wellestablished clinical criteria for diagnosis. 2, 3 Its frequency ranges from 3% in autologous HSCT (auto-HSCT) to 50-60% in the allogeneic setting. 2, 4 In vivo studies conducted in rats that received monocrotaline show that the first morphologic change noted by EM is the loss of sinusoidal endothelial cell (EC) fenestration and the appearance of gaps in the sinusoidal EC barrier (Figure 1b ). These studies also show that the sinusoidal ECs round up, and the RBC begin to penetrate into the space of Disse beneath the ECs and dissect off the endothelial lining (Figure 1c) . Finally, the sloughed sinusoidal lining cells embolize downstream and obstruct sinusoidal flow (Figure 1d ). In these early stages, histological examinations show thickening of the subintimal zone that leads to the narrowing of the venular lumen and an increased resistance to blood flow, which contribute to the haemodynamic changes seen in this disease. Thus, despite the possibility that other factors can contribute to VOD development, endothelial injury seems to be the initiating event in the cascade of events leading to clinical manifestation of this complication. [5] [6] [7] These observations of VOD, the fact that the pathogenesis of the remaining early complication seems to have a close relationship with the microvascular tree (Table 1) , and their overlapping clinical manifestations (Table 2) , are the main reasons these syndromes have been grouped under the denomination of vascular syndromes or vascular endothelial syndromes after HSCT.
Why does HSCT lead to endothelial damage?
The endothelium is an active biologic interface between the blood and all other tissues, and it mediates vaso-motor tone, haemostatic balance and inflammatory reactions, among other functions, throughout the circulatory system. Several input stimuli can produce a local or systemic physiological endothelial activation. The term EC activation includes a wider spectrum of phenotypic changes in the endothelium. This activation takes place in a graded manner rather than an 'all or nothing' response and differs according to several physiological variables, including the location of the vascular bed. When the activating stimulus is too intense or persistent, it can produce a localized or systemic endothelial dysfunction. Currently, the term dysfunction is broadly applied to states in which the EC phenotype poses a net liability to the host. 8 The proposed hypothesis is that, during HSCT, ECs can be activated and damaged by factors such as the chemoradiotherapy included in the conditioning regimen, cytokines produced by the injured tissues, endogenous microbial products translocated through damaged mucosal barriers, 9 drugs used during the procedure (such as G-CSF or calcineurin inhibitors), 10, 11 and the complex process of engraftment. All these factors produce a physiological activation of the EC; however, if they are intense and sustained, the EC activation can evolve into endothelial damage. The different syndromes are determined by the predominant phenotypic change (pro-inflammatory, pro-thrombotic, pro-apoptotic) and its localisation (systemic or organ dependant) ( Figure 2 ).
Moreover, there is clinical evidence suggesting that, in the allogeneic setting, alloreactivity also has a role in the pathogenesis of these endothelial complications. 12, 13 This could explain why these complications are more frequent in allogeneic rather than auto-HSCT, despite identical conditionings being used. In addition, they are more frequent among patients receiving HSCT from unrelated donors, especially if they are mismatched, and the procedures reducing the allogenicity of the graft (such as T-cell depletion) reduce their incidence.
14 Vascular ECs constitute a target tissue for blood-borne executors of the immune system, that is, the antibodies and T-lymphocytes. Transmigration of lymphocytes through the endothelial monolayer involves intimate contact between the two types of cells facilitating EC and T-cell activation. In addition, T-cell-EC contact occurs twice, firstly, when the donor stem cells are administered and secondly, when the newly generated T-lymphocytes enter into the blood stream. This double wave of activation is also suggested by some in vitro studies showing a biphasic evolution of EC activation after allogeneic HSCT (allo-HSCT). 15 Finally, several experimental models propose that vascular ECs are targets for alloreactive and allospecific T-lymphocytes in acute and chronic GVHD. 16 These observations have led to speculations that this early endothelial damage, together with the chronic vascular inflammation observed during chronic GVHD, can have a role in the development of the vascular complications observed later in allo-HSCT, especially when GVHD occurs.
17 Table 2 Clinical manifestations of the vascular endothelial syndromes after HSCT Figure 2 Common pathogenesis of the vascular endothelial syndromes developed early after HSCT. CLS, capillary leak syndrome; CNI, calcineurin inhibitors; DAH, diffuse alveolar haemorrhage; ES, engraftment syndrome; IPS, idiopathic pneumonia syndrome; LPS, lipopolysaccharide; TAM, transplant-associated microangiopathy; VOD, veno-occlusive disease.
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Translational evidence of endothelial dysfunction after HSCT EC injury can be evaluated through the analysis of several coagulation factors, soluble markers or adhesion molecules, the enumeration of circulating ECs (CECs) and microparticles (Figure 3) , and the evaluation of morphologic and functional changes induced in cultured ECs.
Soluble markers and adhesion molecules
Von Willebrand factor (VWF), soluble thrombomodulin (TM), TNF-a, plasminogen activator inhibitor type 1 and soluble adhesion molecules (sE-selectin, sICAM-1, sVCAM-1) are the markers that have been most commonly evaluated. Richard et al. 18 investigated serum levels of VWF, TM, sICAM-1 and TNF-a on days À7, þ 7 and þ 21 in patients receiving auto-or allo-HSCT. Before HSCT, levels of VWF and TM were significantly increased compared with controls. VWF and sICAM, but not TM, were significantly increased on days þ 7 and þ 21. In patients with VOD, only sICAM increased. Catani et al. 19 analysed TM and P-selectin weekly from day 0 to day þ 28 and observed normal levels in all patients, except for those developing severe VOD. Zeigler et al. 20 observed that VWF and TM were increased in all patients with TAM after HSCT. Salat et al. 21 evidenced that VWF and TM rose significantly after conditioning in all patients. At the time of engraftment or at the onset of GVHD, VWF and TM levels were significantly increased with respect to the baseline, especially in patients with acute GVHD grades II-IV, suggesting that ECs could be injured. Nu¨rnberg et al. 22 analysed levels of plasminogen activator inhibitor type 1 and TM and demonstrated that the increases in both markers correlated with the number of vascular complications (VOD, sepsis, capillary leak syndrome) and to a lesser degree with GVHD. Takatsura et al. 23 did not observe any impact of TBI on VWF and TM levels. Matsuda et al. 24 investigated the serum levels of sVCAM-1, sE-selectin and sICAM-1 in HSCT, excluding patients with severe infections. They showed that all soluble adhesion molecules increased after HSCT (day þ 30) and that levels were higher after allo-compared with auto-HSCT. sE-selectin and sVCAM-1 specifically increased in patients with extensive chronic GVHD, and sVCAM-1 increased in patients with TAM. Park et al. 25 evidenced significantly reduced VWF-cleaving protease activity in patients with VOD, even before conditioning. Luzzato et al. 26 also demonstrated an increase in VWF, TM and sE-selectin after HSCT in a paediatric population. Interestingly, when comparing BM, peripheral blood or cord blood HSCT, Rio et al. 27 showed that the increase in VWF and TM levels was absent after cord blood HSCT, suggesting that a tolerance exists between cord blood stem cells and the vascular wall. Recently, Cutler et al. 28 analysed four biomarkers of endothelial injury. They concluded that elevations of VWF, 
Endothelial cells

Endothelial syndromes after HSCT E Carreras and M Diaz-Ricart
TM and sICAM-1 before and early after HSCT may be useful for predicting VOD in patients receiving sirolimus. By attempting to generate a more detailed picture of the endothelial damage after different types of HSCT, our group obtained samples from more than 100 consecutive HSCTs. 15, 29, 30 Samples were drawn before transplant (day Pre), at the time of transplant (day 0), and at different times after auto-and allo-HSCT (days þ 7, þ 14 and þ 21) in patients with or without early complications. Patients with sepsis were excluded. VWF, ADAMTS-13 activity, sVCAM-1, sICAM-1 and sTNFRI were measured. Changes in the levels of most of the markers evaluated were observed, and these changes followed different patterns depending on the type of transplant. VWF and sTNFRI increased progressively from day Pre to day þ 14 for auto-HSCT and to day þ 21 for allo-HSCT. ADAMTS-13 activity was inversely correlated with VWF levels. Levels of sVCAM-1 decreased until day þ 7, and increased up to day þ 14 for auto-HSCT and to day þ 21 for allo-HSCT (Figure 4 ). In contrast, no significant changes were detected for sICAM-1. These results confirmed previous evidence that endothelial damage occurs in the early phases in parallel with the following: (1) the conditioning, (2) the administration of pro-inflammatory (G-CSF) or immunomodulatory agents, (3) the development of mucositis, and (4) the onset of donor leukocyte engraftment. Moreover, the degrees of change in biomarker levels correlated with the intensity of the conditioning treatment and were more relevant in myeloablative compared with reduced-intensity conditioning.
Additionally, the potential diagnostic and/or prognostic utility of the soluble markers as indicators of endotheliumrelated complications in HSCT was explored. Preliminary data shows that levels of soluble biomarkers of endothelial dysfunction are higher in patients with VOD, engraftment syndrome and GVHD. Further studies with a larger number of patients are planned to improve statistical confidence and determine the applicability of one or more of these proteins as suitable diagnostic or prognostic markers of disease. However, all these biological markers seem to be nonspecific, seriously hampered by numerous host factors, and do not allow endothelial dysfunction to be predicted or quantified.
CECs and microparticles
Recently, two further specific markers of endothelial dysfunction have been described, that is, microparticles and CECs. 31, 32 The former have been detected as follicles shed from various types of activated cells, such as platelets, monocytes, polymorphonuclear leukocytes and ECs. Pihusch et al. 33 demonstrated that levels of microparticles increased in patients with acute GVHD, but not in patients without this complication or during conditioning or sepsis. CECs can be isolated and quantified using diverse methods and seem to be an excellent marker of endothelial dysfunction. Elevated levels of CECs reflect the extent of endothelial damage in a variety of disorders. Woywodt et al. 34, 35 demonstrated for the first time in HSCT that patients receiving total body radiation have an earlier peak Bar diagrams represent the density of gold labelling (pixels/mm 2 ). All auto-HSCT were conditioned with BEAM and allo-HSCT with Cy/TBI. *Po0.05 versus Pre condition.
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of CECs compared with patients only receiving chemotherapy. Patients receiving reduced-intensity conditioning have significantly lower CEC counts than those receiving standard conditioning. 35 Our initial studies included the enumeration of CECs. However, we encountered technical problems mainly because of low leukocyte counts in the early stages after HSCT, which made interpretation of the results quite difficult.
In vitro studies with micro-or macrovascular EC cultures EC cultures offer a unique experimental model with which to evaluate endothelial activation and damage, as well as to test agents for preventing or correcting the endothelial dysfunction. The Regensburg university group led these studies for many years. Initially, they demonstrated that ionizing radiations produced apoptosis of micro-and macrovascular ECs, an effect that increased with the presence of the bacterial endotoxins, like lipopolysaccharide. 36 In addition, using human umbilical-vein ECs, they demonstrated that allogenicity has a direct role in EC toxicity, enhancing lipopolysaccharide-mediated EC toxicity. 9 Using microvascular ECs, they further demonstrated that ECs incubated with fludarabine show an increased lysis by allogeneic MHC-restricted cytotoxic T-lymphocytes. 37 Finally, they evaluated microvascular endothelial damage in vitro after allo-HSCT. They observed an increase in the apoptotic activity of the sera from patients at the time of engraftment and preceding episodes of acute and chronic GVHD and TAM. Serum levels of VCAM-1 within the first 100 days also correlated with GVHD. 38 Our group, in collaboration with the Regensburg group, examined the effect of the different types of HSCT and the conditioning regimens applied on the integrity of the endothelium through a series of in vitro studies. 15, 30 We applied a laboratory-based macrovascular cell model to explore more deeply the effect of the soluble plasma factors released during HSCT on resting ECs. We confirmed our previous in vivo results reporting that the allo-and the auto-HSCT resulted in EC activation. The observed effect was characterized by an increase in the expression of cellsurface adhesion receptors (Figure 4) , leukocyte adhesion following exposure to circulating blood, and the activation of the p38 mitogen-activated protein kinase. Additionally, plasma from patients in both settings induced cell proliferation, which was measured by activation of ERK42/44. We observed an increased adhesion of platelets on the extra-cellular matrix (ECM) generated when exposed to blood under flow conditions. This effect correlated with enrichment of the ECM with VWF, but was only clearly significant in the allogeneic setting. Similarly, apoptosis, assessed by measuring activation of the SAPK/JNK pathway, was only observed in the group of allo-HSCT recipients. These observations justify why complications with an inflammatory profile, such as engraftment syndrome and capillary leak syndrome, predominate in auto-HSCT, whereas those with a thrombotic basis, such as VOD or TAM, predominate in allo-HSCT.
Despite our previous observations being generated in the macrovascular cell model, most of the early complications associated with HSCT are bound to the microvasculature. 30 For this reason, we comparatively studied the proinflammatory and pro-thrombotic phenotypes induced by the auto-HSCT environment in the macro-and microvascular locations by using the corresponding cell models. In the autologous setting, activation and damage of both types of cells occurred with similar signs of inflammation, although with a more reactive ECM towards platelets in cells of microvascular origin. This higher reactivity was characterized by increased expression of VWF and tissue factor on the ECM. Because tissue factor is a major activator of the extrinsic pathway of blood coagulation, the synthesis and release of this protein onto the ECM may have important thrombotic consequences at the microvasculature.
Therapeutic strategies to reduce endothelial dysfunction associated with HSCT Several protective agents have been used to prevent or treat VOD after HSCT. 39 In general, results have been disappointing and not always reproducible. Recently, results with defibrotide as a treatment [40] [41] [42] or prophylaxis 43 for VOD, and occasional evidence of its possible efficacy in other endothelial complications, such as TAM, 44 have increased interest in this agent. Interestingly, children receiving prophylactic defibrotide in a randomized study 43 had a lower incidence of VOD and a significantly lower incidence of GVHD. This observation seems to corroborate the suspected relationship between endothelial damage and acute GVHD. Many publications describe the beneficial effects of defibrotide as a pro-fibrinolytic, antithrombotic and thrombolytic, anti-ischemic, anti-shock, anti-atherosclerotic, and anti-rejection drug. 45 Eissner et al. 37 demonstrated in vitro that defibrotide protected ECs from fludarabine toxicity.
Our later studies show that defibrotide prevents the inflammatory reaction through inhibition of p38 mitogenactivated protein kinase and a-serine/threonine-protein kinase activation and of the pro-thrombotic phenotype by blocking changes in the composition of the ECM generated by the sera of patients receiving HSCT. These initial observations could be extended to other drugs, such as oligotide 46 or several antioxidant agents, which have the capability to modulate endothelial activation and dysfunction.
In summary, despite more than 15 years of analysing the role of the endothelium in several of the complications observed after HSCT, our knowledge remains very limited, and it will be necessary to delve further into these studies. However, we have in front of us an attractive scenario that enables us to predict a future in which we could prevent these complications and improve the outcome of patients receiving HSCT.
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